CASP9 and lung cancer: The pretreatment with MitoTEMPO significantly reduced the BA6-induced cytotoxicity, ROS overproduction, and MMP disruption and finally inhibited the caspase-9 and caspase-3 activation and reduced apoptosis (early and late apoptosis) induction in lung cancer cells.